Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry.
Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
Spruce Biosciences announced topline results from two clinical trials, CAHmelia-204 and CAHptain-205, evaluating tildacerfont for congenital adrenal hyperplasia (CAH)....